A Novel and Integrated Approach for the Identification and Characterization of Drug-induced Cardiac Toxicity in the Dog

Toxicologic Pathology

Volumn 39, Issue 2, 2011, Pages 361-371

  Casartelli, Alessandro ^a   Lanzoni, Anna ^a   Comelli, Rodolfo ^a   Crivellente, Federica ^a   Defazio, Rossella ^a   Dorigatti, Roberto ^a   Fasdelli, Nicola ^a   Faustinelli, Ivo ^a   Pagliarusco, Sabrina ^a   Tontodonati, Marcello ^a   Cristofori, Patrizia ^a  

^a GSK   (Italy)

Author keywords

brain natriuretic peptide; cardiac toxicity; cardiac troponin I; cardiotoxicity; Casopitant; dog; phospholipidosis; preclinical development

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CASOPITANT; CREATINE KINASE MB; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DISEASE COURSE; DOG; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; DOGS; DRUG EVALUATION, PRECLINICAL; HEART DISEASES; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, ANIMAL; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PIPERAZINES; PIPERIDINES; RECEPTORS, NEUROKININ-1; TROPONIN I;

CANIS FAMILIARIS;

EID: 79954563475     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310390704     Document Type: Article

References (32)

1. Anderson N. Borlak J. (2006). Drug-induced phospholipidosis. FEBS Lett. 580, 5533–40.
2. Breyer U. Gaertner H.J. (1974). Tissue accumulation of metabolites during chronic administration of piperazine-substituted phenotiazine drugs. The Phenothiazines and Structurally Related Drugs (Forrest I. S. Carr C. J. Usdin E., eds.), Raven Press, New York.
3. Burckhardt D. Raeder E. Műller V. Imhof P. Neubauer H. (1978). Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 239, 213–16.
4. Car B. D. (2006). Enabling technologies in reducing drug attrition due to safety failures. American Drug Discovery 1, 53–56.
5. Cheville F. N. (1994). Ultrastructural Pathology: An Introduction to Interpretation. Iowa State University Press, Ames, IA.
6. Drenckhahn D. Lüllmann-Rauch R. (1979). Experimental myopathy induced by amphiphilic cationinc compounds including several psychotropic. Neuroscience 4, 549–62.
7. Goetze J. P. Mogelvang R. Maage L. Sharling H. Schnohr P. Sogaard P. Rehfeld J. F. Jensen J. S. (2006). Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricula hypertrophy and systolic dysfunction. Eur Heart J 27, 3004–10.
8. Halliwell W. H. (1997). Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 25, 53–60.
9. Ikeda K. Hirayama M. Hirota Y. Asa E. Seki J. Tanaka Y. (2008). Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptormediated targeting of lysosomal enzymes. Biochem Biophys Res Commun. 377, 268–74.
10. Ishii J. Cui W. Kitagawa F. Kuno T. Nakamura Y. Naruse H. Mori Y. Ishikawa T. Nagamura Y. Kondo T. Oshima H. Nomura M. Ezaki K. Hishida H. (2003). Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 49, 2020–26.
11. Jagel M. Lüllmann-Rauch R. (1984). Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics. Arch Toxicol 55, 229–32.
12. Jefferson J. W. (1975). A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med 37, 160–79.
13. Kacew S. Reasor M.J. Ruben Z. (1997). Cationic lipophilic drugs: Mechanisms of action, potential consequences, and reversibility. Drug Metabol Rev 291, 355–68.
14. Kang J. Y. (2006). Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol 35, 58–66.
15. Lafuente C. L. Alvarez J. C. Leenhardt A. Mouly S. Extramiana F. Caulin C. Brentano C. F. Bergmann J. F. (2009). Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br J Clin Pharmacol. 67, 511–19.
16. Lüllmann-Rauch R. (1979). Drug-induced lysosomal storage disorders. In Lysosomes in Applied Biology and Therapeutics (Dingle J. T. Jaques P. J. Shaw I. H., eds.), vol. 6, North-Holland Publishing Company, Amsterdam–New York–Oxford.
17. Miraglia L. Pagliarusco S. Bordini E. Martinucci S. Pellegatti M. (2010). Metabolic disposition of casopitant, a potent NK1 receptor antagonist, in mice, rats and dogs. Drug Metab Dispos 38, 1876–91.
18. Missouris G. G. Kalaitzidis R. G. Cappuccio F. P. MacGregor G. A. (2000). Gingival hyperplasia caused by calcium channel blockers. J Hum Hypertens 14, 155–56.
19. Monro A. M. (1990). Interspecies comparison in toxicology: the utility and futility of plasma concentrations of the test substance. Regulatory toxicology and pharmacology 12, 137–160.
20. Morello A. M. Januzzi J. L. (2006). Amino-terminal pro-brain natriuretic peptide: A biomarker for diagnosis, prognosis and management of heart failure. Expert Rev Mol Diagn. 6, 649–62.
21. Mortuza G. B. Neville W. A. Delany J. Waterfield C. J. Camilleri P. (2003). Characterisation of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochim Biophys Acta 1631, 136–46.
22. Nonoyama T. Fukuda R. (2008). Drug-induced phospholipidosis-pathological aspects and its prediction. J Toxicol Pathol 21, 9–24.
23. Olson H. Betton G. Robinson D. Thomas K. Monro A. Kolaja G. Lilly P. Sanders J. Sipes G. Bracken W. Dorato M. Van Deun K. Smith P. Berger B. Heller A. (2000). Concordance of the toxicity of pharmaceuticals in humans and animals. Regul Toxicol Pharmacol 32, 56–67.
24. Oyama M. A. Solter P. F. (2004). Validation of an immunoassay for measurement of canine cardiac troponin-I. J Vet Cardiol 6, 17–24.
25. Panou F. K. Kotseroglou V. K. Lakoumentas J. A. Chrysanthopoulou S. A. Armeniakos J. A. Stratigou T. Veve H. Zacharoulis A. A. (2006). Significance of brain natriuretic peptide in the evaluation of symptoms and degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomiopathy. Hellenic J Cardiol 47, 344–51.
26. S.W., Rabkin, Effect of amiodarone on phospholipid content and composition in heart, lung, kidney and skeletal muscle: Relationship to alteration of thyroid function, Pharmacology, (2006), 76, 129-135
27. Reasor M. J. Hastings K. L. Ulrich R. G. (2006). Drug-induced phospholipidosis: Issues and future directions. Exp Opin Drug Saf 5, 567–83.
28. Roos J. M. Aubry M. C. Edwards W. D. (2002). Chloroquine cardiotoxicity clinicopathologic features in three patients and comparison with three patients with Fabry disease. Cardiovasc Pathol 11, 277–83.
29. Schneider P. (1992). Drug-induced lysosomal disorders in laboratory animals: New substances acting on lysosomes. Arch Toxicol 66, 23–33.
30. Shaikh N.A. Downar E. (1987). Effects of chronic amiodarone treatment on cat myocardial phospholipid content and on in vitro phospholipid catabolism. Mol Cell Biochem 78, 17–25.
31. Van Vleet J. F. Ferrans V. J. Herman E. (1991). Cardiovascular and skeletal muscle system. In Toxicologic Pathology (Haschek W. M. Rousseaux C. G., eds.), pp. 363–446, Academic Press, San Diego, CA.
32. Vonderfecht S. L. Stone M. L. Eversole R. R. Yancey M. F. Schuette M. R. Duncan B. A. Ware J. A. (2004). Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol. 32, 318–25.